August 2013, Vol 2, No 5

Antiangiogenic Tyrosine Kinase Inhibitors and Their Diverse Spectra of Inhibitory Activity: Implications for Personalized Therapy in Renal Cell Carcinoma

Key Points Introduction of multiple VEGFR TKIs with slightly different inhibition profiles lends itself to increasingly personalized treatments Tumor heterogeneity may complicate this approach Multiple biopsies may better determine the overall mutational burden of an RCC tumor, but this strategy is hampered by practical limitations and cost of technology We [ Read More ]

Sanjiv S. Agarwala, MD


Providing Molecular Profiling for Patients With Ovarian Cancer:

An Interview with Laura Shawver, PhD, of The Clearity Foundation

The Clearity Foundation was launched in 2008 to help patients with ovarian cancer and their physicians make better-informed treatment decisions based on the molecular profiling of tumors. The Clearity team includes scientists, physicians, and volunteers who feel passionately that the paradigm for recurrent ovarian cancer treatment needs to change from [ Read More ]

Laura K. Shawver, PhD

Interview with the Innovators

Immune-Related Endocrinopathies Associated With Ipilimumab Therapy

With the recent advancements in the treatment of patients with metastatic melanoma, in particular with immunomodulating therapies, the development of unique immune-related side effects has posed novel management challenges. The first drug in this class to receive FDA approval for the treatment of unresectable stage III or IV melanoma is [ Read More ]

Le Min, MD, PhD


ASCO President Focuses on Bridges to Conquer Cancer

“Building Bridges to Conquer Cancer” was the theme of the 2013 Annual Meeting of the American Society of Clinical Oncology (ASCO), as well as the address of ASCO president Sandra M. Swain, MD. Her address focused on 3 pillars of the theme: 1) ensuring global health equity, 2) the need [ Read More ]

Wayne Kuznar


Multiple Myeloma: Novel Agents Emerge in Initial Therapy, Refractory Setting

Advances in the understanding of the biology of multiple myeloma (MM) and the identification of new drugs have resulted in improved management of MM, including patients who are refractory to proteasome inhibitors and immunomodulatory agents.An update on initial therapy was offered by Donna E. Reece, MD, director, Program for Multiple [ Read More ]

Wayne Kuznar


Ten Years of Tamoxifen Is Superior to 5 Years in ER+ Breast Cancer

Ten years of adjuvant tamoxifen is superior to 5 years in reducing the rates of late recurrence and death in women with estrogen receptor (ER)-positive breast cancer, reported Richard G. Gray, MSc. Previously, 5 years of tamoxifen have been shown to reduce breast cancer mortality by about one-third over 15 [ Read More ]

Wayne Kuznar


Immunotherapy in Cancer Care: Personalized or Population-Based Medicine…and the Janusian Factor

Is immunotherapy a type of personalized medicine (PM) or just useful population-based medicine? Look in different directions and you’ll get different answers, but whatever we do, let’s avoid oversimplification. For when we get down to specifics, the accurate answer is, “It depends.” When in doubt, it is often useful to [ Read More ]

Robert E. Henry

The Last Word

The Role of Immunotherapies in Personalized Medicine

Dear Colleague,As personalized medicine (PM) continues to expand its presence in cancer care, the need for clarity of its mission increases along with it. In this issue of Personalized Medicine in Oncology (PMO), we examine the expansion of immunotherapy in The Last Word column, which draws out the need for [ Read More ]

Kenneth Bloom, MD